Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:9/10/2007

VIENNA, Va., Sept. 10 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI CORPORATION (Amex: CVM) to its shareholders:

Dear Fellow Shareholders:

The past 12 months have been the most successful ever for CEL-SCI Corporation. The U.S. Food and Drug Administration (FDA) granted us the go- ahead for a Phase III (last phase) clinical trial with our cancer drug Multikine(R) and also granted Multikine Orphan drug designation. Following the excellent developments at the Company, we were able to raise $30 million, half in equity and the other half in the form of the acquisition and build out of a manufacturing facility for Multikine which will then be leased to us for 20 years. We feel that we finally have the ability to move forward rapidly since CEL-SCI is now properly financed and all the pieces have fallen into place.

These recent successes follow years of difficulty when we operated with very little capital and the path to the marketing approval for Multikine was not yet clear. We believe that there is a high likelihood of being successful in the upcoming Phase III study because 1) we have designed the study to require a much lower level of improvement in overall survival than the 33% improvement in overall survival we saw in our last Phase II study, and 2) Multikine so far has been shown to be safe, and well tolerated. It is toxic only to cancer cells.

Our goal is to receive world-wide marketing approval for Multikine as a first line standard of care drug for advanced primary head and neck cancer patients. We are not aware of any other biotech company that has ever gone for first line standard of care in cancer as its first indication. Typically drugs are developed and appro
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
2. CEL-SCI Presents Long-Term Cancer Survival Data With Multikine
3. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
4. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
5. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
6. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
7. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
8. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
9. Insmed Releases Positive Results from Iplex Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
10. State of Diabetes in Pittsburgh: Pittsburgh Business Group on Health Releases Report
11. Bipolar Disorder in Children Difficult to Diagnose, Reports the Harvard Mental Health Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 The Pulmonary Fibrosis ... data from more than 1,100 patients and families suffering ... Drug Administration (FDA) for the Patient-Focused Drug Development Meeting ... a new FDA initiative to seek patient input in ... therapeutic treatments. "We applaud the FDA for ...
(Date:9/16/2014)... , Sept. 16, 2014 Astellas announced ... of Business Communications & Advocacy, Urology in the ... Communications & Advocacy Margaret Long. In this role, Noland ... urology to patient and advocacy organizations, as well ... key strategic initiatives. Noland,s appointment is the latest ...
(Date:9/16/2014)... 2014  Aratana Therapeutics, Inc. (NASDAQ: ... licensing, developing and commercializing innovative biopharmaceutical products for ... an underwritten registered public offering of shares of ... being offered by Aratana Therapeutics. ... book-running managers for the offering.  ...
Breaking Medicine Technology:PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 2PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 3PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 4Christy Noland to Lead Urology Advocacy and Communications for Astellas 2Aratana Therapeutics, Inc. Announces Proposed Public Offering 2
... Oct. 11 Merial, the Animal Health division ... ), announced today that Merial Animal Health Co. (China) held ... located in the Nanchang Hi-tech Development Zone, China. Merial ... the Group,s first production facility in China has been in ...
... , EXTON, Pa., Oct. 9 Kensey Nash Corporation (Nasdaq: ... earnings results for its first quarter ended September 30, 2009 ... , Joe Kaufmann, President and CEO, will be ... 22, 2009 at 9:00 A.M. Eastern Time. , ...
Cached Medicine Technology:Merial invests US $70 million in Nanchang, China 2Merial invests US $70 million in Nanchang, China 3Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference 2
(Date:9/16/2014)... Paradigm Physical Therapy is proud to announce ... for their patients. Dry needling is a procedure that ... musculoskeletal problems. , In this invasive procedure, a solid ... and muscle to create a trigger point. Using repeated ... to deactivate and release the trigger point within seconds. ...
(Date:9/16/2014)... Florida (PRWEB) September 16, 2014 These new ... last 3 years to receive up to $10,000 in a ... program, as well as other state and federal programs, are ... to be paid back until you sell or move out ... is a 0% interest loan. There are no monthly payments ...
(Date:9/16/2014)... magnesium sulfate is routinely given to pregnant women at ... won,t provide any long-term benefits for infants. ... pregnant women, researchers in Australia found it had no ... those children when they were assessed at between 6 ... negate the fact that the drug is helpful in ...
(Date:9/16/2014)... able to predict when and how much various treatments ... part to new findings that researchers at Fox Chase ... Oncology,s 56th Annual Meeting on Tuesday, September 16. , ... completed by men diagnosed with prostate cancer, Fox Chase ... following each type of treatment, and by how much. ...
(Date:9/16/2014)... September 16, 2014 This year’s theme ... and Sustainable company Glen Mills, Pennsylvania, September 15, 2014- ... one of the fastest growing companies in the country, ... flower, shrub, and tree health-care by naturally decreasing disease ... development. Today it announced that it will hold its ...
Breaking Medicine News(10 mins):Health News:Paradigm Physical Therapy Introduces Dry Needling 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 3Health News:Researchers Don't See Long-Term Benefits From Drug for Preemies 2Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 2Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 3Health News:Holganix Holds 3rd Annual Bionutritional Summit in Louisville, Kentucky 2
... Calif., May 27 The Ensign,Group, Inc. (Nasdaq: ... Ensign(TM) group of,skilled nursing, rehabilitative care services and ... in the FBR Capital,Markets 12th Annual Spring Investor ... in New York City. Christopher Christensen, CEO, together ...
... provide the infrastructure for MRF,s collaborative ... ... 27 Collaborative Drug,Discovery, Inc. (CDD) announced today that its ... new drug,candidates, has been selected by the Myelin Repair Foundation ...
... infection following operations for which a "prophylactic" antibiotic is ... than it was just a decade ago, according to ... report their findings in the June 15 issue of ... that have been associated with severe infections, such as ...
... dad is more involved in baby,care than ever before. Whether ... basics, or a new dad to whom the dear wife ... to pack in the "diaper,dude":, The Moms on Call ... pediatric nurse moms, is a guidebook for new dads that ...
... study says , , TUESDAY, May 27 (HealthDay News) -- A ... in nonsmokers, researchers report. , The findings -- that certain ... lung cancer, regardless of whether he or she ever smoked ... said study author Dr. Ping Yang, of the Mayo Clinic. ...
... 27 Somanetics Corporation,(Nasdaq: SMTS ) announced today ... and Drug Administration (FDA) to expand the labeling for ... 510(k) will serve to support our ongoing efforts,in the ... said,Bruce Barrett, Somanetics, president and CEO. "First, the 510(k) ...
Cached Medicine News:Health News:The Ensign Group to Present at the FBR Capital Markets 12th Annual Spring Investor Conference on May 29th 2Health News:The Ensign Group to Present at the FBR Capital Markets 12th Annual Spring Investor Conference on May 29th 3Health News:Collaborative Drug Discovery and Myelin Repair Foundation Announce Partnership 2Health News:Collaborative Drug Discovery and Myelin Repair Foundation Announce Partnership 3Health News:Collaborative Drug Discovery and Myelin Repair Foundation Announce Partnership 4Health News:The balance shifts 2Health News:Father's Day is Almost Here: Two Pediatric Nurses, Moms, Offer Practical Guidebook & DVD for New Dads 2Health News:Common Genetic Variant Tied to Lung Cancer Risk 2Health News:Common Genetic Variant Tied to Lung Cancer Risk 3Health News:Somanetics Receives 510(k) Clearance From the FDA to Expand INVOS System Labeling 2
Featuring a secure and tamper-evident adhesive closure, computer-generated Smart ScanBand can be simultaneously printed with bar code information and programmed with RFID information....
Safe. Reliable. Baby-friendly. ,The Hugs infant protection system helps to protect your infants and children from the threat of abduction....
VerdaSee Portal ID is a family of solutions that provide automated tracking and tracing of assets as they enter or leave designated areas within a healthcare facility....
... Agility is positioned to support ... to reduce medication and other ... workflow for pharmacy support staff ... blood products, lab specimens and ...
Medicine Products: